Skip to main content
. 2021 Feb 4;9(1):6. doi: 10.3390/medsci9010006

Table 1.

Baseline cohort characteristics including univariate logistic regression analyses and associated p values. Odds ratios are stated per 1 unit increase in the independent variable unless otherwise stated.

N Cohort (316) Survived (231) Died (84) Univariate ORdeath (95% CI) p
Age (years) 316 75 (60–83) 69 (56–80) 82 (76–89) 1.08 (1.06–1.11) <0.001
Male sex 316 173 (54.7) 124 (53.6) 48 (57.1) 1.15 (0.70–1.91) 0.585
Fever 316 211 (66.8) 165 (71.4) 46 (54.8) 0.48 (0.29–0.81) 0.006
Cough 316 224 (70.9) 169 (73.2) 55 (65.5) 0.70 (0.41–1.20) 0.184
Sputum 316 76 (24.1) 63 (27.3) 13 (15.5) 0.49 (0.24–0.92) 0.033
Breathlessness 316 197 (62.3) 136 (58.9) 61 (72.6) 1.85 (1.08–3.25) 0.027
Any comorbidity a 316 250 (79.1) 171 (74.0) 78 (92.9) 4.56 (2.03–12.2) 0.001
Respiratory comorbidity b 316 101 (32.0) 78 (33.8) 23 (27.4) 0.74 (0.42–1.27) 0.284
Immunosuppression c 316 27 (8.5) 17 (7.4) 9 (10.7) 1.51 (0.62–3.46) 0.341
Dementia 316 55 (17.4) 29 (12.6) 26 (31.0) 3.12 (1.70–5.73) <0.001
Healthcare worker 316 27 (8.5) 27 (11.7) 0 (0) na na
Admitted from nursing or residential home 316 60 (19.0) 27 (11.7) 33 (39.3) 4.89 (2.71–8.92) <0.001
Clinical frailty score 311 4 (2–6) 3 (2–5) 6 (4–7) 1.61 (1.40–1.87) <0.001
Severe COVID-19 308 174/308 (56.5%) 85/225 (37.8) 51/83 (61.4) 2.62 (1.57–4.44) <0.001
Haemoglobin (115–165 g/L) 310 134 (115–145) 135 (117–145) 130 (115–145) 0.95 (0.84–1.07) f 0.390
Lymphocytes (1–4 × 109/L) 311 0.88 (0.64–1.32) 0.92 (0.65–1.33) 0.82 (0.62–1.32) 0.99 (0.87–1.07) 0.882
Neutrophils (2–7 × 109/L) 311 5.30 (3.70–7.48) 5.01 (3.54–7.09) 7.24 (4.37–9.30) 1.17 (1.08–1.26) <0.001
eGFR (>90 mL/min.1.73 m2) 307 68 (44–89) 76 (53–>90) 52 (32–74) 0.88 (0.83–0.92) g <0.001
CRP (<5 mg/L) 306 72 (30–131) 65 (23–119) 90 (50–176) 1.04 (1.01–1.06) f 0.007
Hypoxia d 308 192/308 (62.3) 129/225 (57.3) 63/83 (75.9) 2.75 (1.64–4.64) <0.001
Definite COVID-19 on baseline CXR 303 121/303 (39.9) 88/219 (40.2) 32/83 (38.6) 0.93 (0.55–1.56) 0.796
CURB65 score e 299 2 (1–2) 1 (0–2) 2 (1–3) 2.20 (1.67–2.95) <0.001

Data are median (IQR: interquartile range) for continuous variables, and n (%) (or n/N (%)) for categorical variables. Local laboratory normal ranges for blood tests are shown in parentheses. a Presence of at least one of respiratory comorbidity, heart failure, diabetes, active cancer or immunosuppression. b Defined as at least one of: asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, obstructive sleep apnoea, home nebuliser/oxygen/non-invasive pressure support. c Defined as at least one of: immunodeficiency syndrome, maintenance steroids (prednisolone ≥ 5 mg/day, hydrocortisone ≥ 15 mg/day, any dose dexamethasone); conventional synthetic immunosuppressive drugs (excluding hydroxychloroquine and sulfasalazine); biologics; Janus kinase (JAK) inhibitors; cytotoxic chemotherapy within past 6 months. d Defined as oxygen saturations ≤ 94% on room air, or any use of supplemental oxygen. e CURB65 with 1 point each for confusion, urea > 7, respiratory rate > 30, systolic blood pressure < 90 mmHg or 60 mmHg diastolic, and age ≥ 65. f OR stated per 10 unit increase in haemoglobin/CRP. g OR stated per 5 unit increase in eGFR. CRP: C-reactive protein, COPD: chronic obstructive pulmonary disease, CXR: chest x-ray, eGFR: estimated glomerular filtration rate, IQR: interquartile range, N: total number of measurements for each variable for the entire cohort, OR: odds ratio.